Skip to main content

Our recent activity

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs. The merged company will focus on developing therapeutics that translate growth factor signaling pathways into innovative therapies for the treatment of fibrosis related diseases.

“Through this acquisition, we have taken a big step in broadening our clinical-stage pipeline and are ultimately one step closer to bringing meaningful treatments to patients with fibrotic diseases. The synergies between Origo’s unique small molecule platform and Agomab’s antibody capabilities, combined with our collective expertise in targeting growth factors, will allow us to accelerate the development of novel therapeutic candidates,” said Paul van der Horst, Chief Business Officer at Agomab Therapeutics. “We would like to thank all the parties who have supported the completion of this transaction.”

Agomab will integrate the full Origo team as well as its facilities in Touro and Barcelona in Spain into its current organization, complimenting Agomab’s headquarters in Belgium and research laboratories in Italy.

About Agomab

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

PortfolioOna Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
October 14, 2025

Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development

• Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo • Led the development and approval of multiple breakthrough medicines…
PortfolioAltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
October 2, 2025

AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys

READ THIS NEWS IN SPANISH The resulting team will manage over €400M in investments in biotechnology and medical technologies. Management of the Alta Life Sciences Spain I FCR fund will…
PortfolioAsabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
September 10, 2025

Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®

READ THIS NEWS IN SPANISH Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to…